• Something wrong with this record ?

Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents

I. Truxova, M. Hensler, P. Skapa, MJ. Halaska, J. Laco, A. Ryska, R. Spisek, J. Fucikova,

. 2017 ; 330 (-) : 115-156. [pub] 20161129

Language English Country Netherlands

Document type Journal Article, Review, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18016763

Owing to their central role in the initiation and regulation of antitumor immunity, dendritic cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several encouraging clinical applications, existing DC-based immunotherapy efforts have yielded inconsistent results. Recent work has identified strategies that may allow for more potent DC-based vaccines, such as the combination with antitumor agents that have the potential to synergistically enhance DC functions. Selected cytotoxic agents may stimulate DCs either by directly promoting their maturation or through the induction of immunogenic tumor cell death. Moreover, they may support DC-induced adaptive immune responses by disrupting tumor-induced immunosuppressive mechanisms via selective depletion or inhibition of regulatory subsets, such as myeloid-derived suppressor cells and/or regulatory T cells (Tregs). Here, we summarize our current knowledge on the capacity of anticancer chemotherapeutics to modulate DC phenotype and functions and the results of ongoing clinical trials evaluating the use of DC-based immunotherapy in combination with chemotherapy in cancer patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016763
003      
CZ-PrNML
005      
20180523110319.0
007      
ta
008      
180515s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/bs.ircmb.2016.09.003 $2 doi
035    __
$a (PubMed)28215530
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Truxova, I $u 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
245    10
$a Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents / $c I. Truxova, M. Hensler, P. Skapa, MJ. Halaska, J. Laco, A. Ryska, R. Spisek, J. Fucikova,
520    9_
$a Owing to their central role in the initiation and regulation of antitumor immunity, dendritic cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several encouraging clinical applications, existing DC-based immunotherapy efforts have yielded inconsistent results. Recent work has identified strategies that may allow for more potent DC-based vaccines, such as the combination with antitumor agents that have the potential to synergistically enhance DC functions. Selected cytotoxic agents may stimulate DCs either by directly promoting their maturation or through the induction of immunogenic tumor cell death. Moreover, they may support DC-induced adaptive immune responses by disrupting tumor-induced immunosuppressive mechanisms via selective depletion or inhibition of regulatory subsets, such as myeloid-derived suppressor cells and/or regulatory T cells (Tregs). Here, we summarize our current knowledge on the capacity of anticancer chemotherapeutics to modulate DC phenotype and functions and the results of ongoing clinical trials evaluating the use of DC-based immunotherapy in combination with chemotherapy in cancer patients.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a protinádorové vakcíny $x imunologie $7 D019496
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a dendritické buňky $x imunologie $7 D003713
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $7 D007167
650    12
$a vakcinace $7 D014611
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hensler, M $u Sotio a.s., Prague, Czech Republic.
700    1_
$a Skapa, P $u 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Halaska, M J $u 3rd Faculty of Medicine and Faculty Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic.
700    1_
$a Laco, J $u Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Prague, Czech Republic.
700    1_
$a Ryska, A $u Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Prague, Czech Republic.
700    1_
$a Spisek, R $u 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
700    1_
$a Fucikova, J $u 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic. Electronic address: fucikova@sotio.com.
773    0_
$w MED00186216 $t International review of cell and molecular biology $x 1937-6448 $g Roč. 330, č. - (2017), s. 115-156
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28215530 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180523110504 $b ABA008
999    __
$a ok $b bmc $g 1300387 $s 1013603
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 330 $c - $d 115-156 $e 20161129 $i 1937-6448 $m International review of cell and molecular biology $n Int Rev Cell Mol Biol $x MED00186216
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options